A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01285752

Enrollment

240

Registered

2011-01-28

Start date

2011-02-28

Completion date

2012-12-31

Last updated

2016-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.

Interventions

DRUGAK106-001616

DRUGActive comparator

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of RA (class I to III) * Stable dose of methotrexate (at least 12 weeks)

Exclusion criteria

* Pregnant or breastfeeding * Abnormal screening laboratory test values considered to be clinically significant

Countries

Czechia, Germany, Hungary, Poland, Slovakia, Ukraine, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026